The federal hiring freeze implemented by the Trump Administration adds another challenge to the ongoing struggle by FDA’s Center for Drug Evaluation & Research to recruit and retain qualified individuals to fill both open executive leadership positions and vacancies within its drug review teams.
While CDER’s recruitment challenges are longstanding and well-publicized by the 21st Century Cures legislative discussion, the Jan. 23